NanoSphere Health Sciences Inc. (NSHSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoSphere Health Sciences Inc. (NSHSF) trades at $0.01 with AI Score 48/100 (Grade C). NanoSphere Health Sciences Inc. is a nano-biotechnology company based in Vancouver, Canada, specializing in advanced bio-delivery systems. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for NSHSF: NSHSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NSHSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NSHSF: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NanoSphere Health Sciences Inc. (NSHSF) Healthcare & Pipeline Overview
NanoSphere Health Sciences Inc. is a nano-biotechnology firm headquartered in Vancouver, Canada, specializing in advanced bio-delivery systems. Its proprietary NanoSphere Delivery System utilizes nanotechnology to enhance the absorption of compounds across cannabis, pharmaceutical, and animal health sectors in the U.S. and Canada, aiming to improve efficacy and bioavailability.
What Is the Investment Thesis for NSHSF?
NanoSphere Health Sciences Inc. presents a research focus centered on its proprietary NanoSphere Delivery System, a nanotechnology-based platform designed to enhance the bioavailability of various compounds. The thesis revolves around the potential for this system to disrupt traditional delivery methods across multiple industries. With a market capitalization of $0.00B and a Beta of 0.41, the company exhibits low market volatility relative to the broader market. The primary value driver is the broad applicability of its NanoSphere Delivery System, which can be licensed or integrated into products within the cannabis, pharmaceutical, and animal health sectors. Growth catalysts include potential new partnerships or licensing agreements for its technology, expansion into new product categories leveraging enhanced absorption, and increased market penetration within its existing target industries. The company's ability to demonstrate superior efficacy and absorption rates compared to conventional delivery methods could drive adoption. However, as an OTC-traded company with an "Unknown" disclosure status, potential investors face inherent risks related to liquidity, transparency, and regulatory oversight, which are critical considerations for evaluating its long-term viability and growth trajectory.
Based on FMP financials and quantitative analysis
NSHSF Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap company with potentially higher volatility and lower liquidity.
- Beta: 0.41, suggesting lower price volatility relative to the broader market.
- Dividend Yield: None, as the company does not currently pay dividends.
- Core Technology: Proprietary NanoSphere Delivery System, leveraging nanotechnology for enhanced compound absorption.
- Target Markets: Strategic focus on cannabis, pharmaceutical, and animal health industries in the U.S. and Canada.
Who Are NSHSF's Competitors?
NSHSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NSHSF's Key Strengths?
Proprietary NanoSphere Delivery System leveraging advanced nanotechnology.
- Broad applicability of technology across multiple high-growth sectors (cannabis, pharma, animal health).
- Focus on enhancing bioavailability, addressing a key industry challenge.
- Established presence in both the United States and Canada.
What Are NSHSF's Weaknesses?
Small market capitalization ($0.00B) indicating limited resources and market presence.
- "OTC Other" tier and "Unknown" disclosure status, implying limited transparency and regulatory oversight.
- Reliance on a single core technology (NanoSphere Delivery System) for growth.
- Potential challenges in scaling production and securing large-scale partnerships.
What Could Drive NSHSF Stock Higher?
NSHSF catalyst: Potential announcement of new licensing agreements for the NanoSphere Delivery System in the cannabis or pharmaceutical sectors.
- Regulatory approvals for new applications or products utilizing NanoSphere's technology in specific markets.
- Continued development and refinement of the NanoSphere Delivery System, potentially leading to expanded applications.
- Strategic partnerships aimed at increasing market penetration and product distribution in North America.
What Are the Key Risks for NSHSF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant competition from larger, better-funded biotechnology and pharmaceutical companies.
- Regulatory uncertainty and evolving legal frameworks in the cannabis and pharmaceutical industries.
- Challenges associated with OTC trading, including low liquidity, limited transparency, and potential for price volatility.
- Difficulty in securing substantial funding or capital for research, development, and market expansion given its market cap.
- Dependence on the successful commercialization and adoption of a single core technology, the NanoSphere Delivery System.
What Are the Growth Opportunities for NSHSF?
- Expansion in the Cannabis Sector: The global legal cannabis market is experiencing robust growth, projected to reach significant valuations in the coming years. NanoSphere's NanoSphere Delivery System, by enhancing the bioavailability and speed of onset for cannabinoids, offers a compelling advantage for cannabis product manufacturers. This technology can lead to more consistent and effective products, appealing to both recreational and medicinal users seeking optimized experiences. Further licensing agreements with major cannabis brands or direct product development in this sector, particularly in newly legalized states or provinces, represent a substantial growth avenue. The timeline for this growth is ongoing, driven by evolving regulatory landscapes and increasing consumer demand for advanced cannabis products.
- Pharmaceutical Partnerships and Licensing: The pharmaceutical industry continuously seeks innovative drug delivery methods to improve patient outcomes, reduce side effects, and extend patent life. NanoSphere's technology could be licensed to pharmaceutical companies for existing drug reformulations or new drug development, particularly for compounds with poor oral bioavailability. This could lead to more effective treatments, lower required dosages, and improved patient compliance. The market for advanced drug delivery systems is substantial, with nanotechnology playing an increasing role. Securing a significant partnership with a mid-to-large pharmaceutical firm could unlock substantial revenue streams and provide validation for the NanoSphere Delivery System, with potential timelines for clinical trials and product launches spanning several years.
- Penetration into the Animal Health Market: The animal health sector, including veterinary pharmaceuticals and pet supplements, is a growing market driven by increased pet ownership and a willingness to spend on animal welfare. NanoSphere's system can improve the delivery of medications and supplements for animals, leading to better absorption and efficacy for a wide range of conditions. This could translate into more effective treatments for pets and livestock, enhancing their health and quality of life. Opportunities exist for partnerships with animal pharmaceutical companies or direct-to-consumer product lines. This market segment offers a less regulated entry point compared to human pharmaceuticals, potentially allowing for faster product development and market entry within a 1-3 year timeframe.
- Development of Nutraceutical and Supplement Products: The global nutraceuticals market is expanding rapidly, fueled by consumer demand for health and wellness products. Many vitamins, minerals, and herbal extracts suffer from poor absorption, limiting their effectiveness. The NanoSphere Delivery System can significantly improve the bioavailability of these compounds, allowing for more potent and effective supplements. This could enable NanoSphere to develop its own branded line of high-efficacy nutraceuticals or license its technology to existing supplement manufacturers, capturing a share of this multi-billion dollar market. The timeline for new product introductions in this sector can be relatively shorter, potentially within 1-2 years, given fewer regulatory hurdles compared to prescription drugs.
- Geographic Expansion within North America: While NanoSphere Health Sciences Inc. currently operates in both the United States and Canada, there is potential for deeper market penetration and expansion within specific regions or states. As regulatory environments evolve, particularly concerning cannabis, new opportunities arise for the company to introduce its technology and products to untapped markets. Focusing on areas with high population density or significant growth in target industries could yield substantial returns. This involves strategic partnerships, localized marketing efforts, and navigating regional regulatory nuances. This expansion is an ongoing process, with new opportunities emerging as market conditions and regulatory frameworks continue to develop across North America.
What Threats Does NSHSF Face?
- Intense competition from larger pharmaceutical and biotech companies with greater R&D budgets.
- Regulatory hurdles and evolving legal frameworks in cannabis and pharmaceutical sectors.
- Challenges associated with OTC trading, including low liquidity and investor confidence.
- Risk of technological obsolescence or emergence of superior delivery technologies.
What Are NSHSF's Competitive Advantages?
- Proprietary NanoSphere Delivery System, a patented nanotechnology platform for enhanced absorption.
- Multi-industry application (cannabis, pharma, animal health) diversifying revenue potential.
- Focus on improving bioavailability, addressing a critical challenge in drug and supplement efficacy.
- Early mover advantage in applying advanced nanotechnology to specific niche markets like cannabis delivery.
What Does NSHSF Do?
NanoSphere Health Sciences Inc., established in 2005 and headquartered in Vancouver, Canada, operates as a pioneering nano-biotechnology enterprise with a strategic focus on the provision of biologically active compounds across both the United States and Canada. The company's core innovation is the NanoSphere Delivery System, an advanced technological platform engineered to significantly enhance the biological absorption and bioavailability of various substances. This proprietary system leverages cutting-edge nanotechnology principles to encapsulate and deliver supplements, nutraceuticals, and non-prescription drugs more effectively within the body. By improving the cellular uptake and systemic distribution of these compounds, NanoSphere aims to maximize their therapeutic potential and overall efficacy, addressing a critical challenge in drug and supplement delivery. The versatility of the NanoSphere Delivery System allows it to serve a diverse array of industries, demonstrating its broad applicability and market potential. Key sectors benefiting from this technology include the rapidly evolving cannabis industry, where enhanced cannabinoid delivery can improve product performance and consumer experience through faster onset and increased potency; the pharmaceutical sector, offering potential for more efficient drug formulations, reduced dosages, and improved patient compliance; and the animal health industry, providing improved delivery mechanisms for veterinary medications and supplements, thereby enhancing animal welfare and treatment outcomes. This multi-sector approach underscores NanoSphere Health Sciences Inc.'s commitment to applying its nano-biotechnology expertise to address critical delivery challenges in human and animal health and wellness markets. The company’s strategic positioning in these high-growth sectors, coupled with its focus on a foundational delivery technology, defines its market presence and long-term objectives in the bio-delivery space, aiming to establish its system as a preferred method for advanced compound delivery.
What Products and Services Does NSHSF Offer?
- Develops and commercializes a proprietary NanoSphere Delivery System.
- Utilizes nanotechnology to enhance the biological absorption of compounds.
- Focuses on improving the bioavailability of supplements, nutraceuticals, and non-prescription drugs.
- Applies its technology across the cannabis industry for enhanced cannabinoid delivery.
- Offers solutions for the pharmaceutical sector to improve drug efficacy.
- Provides advanced delivery mechanisms for the animal health industry.
- Operates in both the United States and Canada.
How Does NSHSF Make Money?
- Licensing its NanoSphere Delivery System to other companies in target industries (cannabis, pharma, animal health).
- Potential for direct product development and sales leveraging its proprietary delivery technology.
- Collaborations and joint ventures for specific product formulations or market entries.
What Industry Does NSHSF Operate In?
NanoSphere Health Sciences Inc. operates within the dynamic and innovation-driven biotechnology sector, specifically focusing on advanced drug and supplement delivery systems. The broader healthcare industry is increasingly seeking solutions to improve the efficacy and patient experience of therapeutic compounds, with nanotechnology emerging as a key enabler. The global nanomedicine market, for instance, is projected to grow significantly, driven by demand for targeted drug delivery and enhanced bioavailability. NanoSphere's NanoSphere Delivery System positions the company within this high-growth niche, aiming to address challenges such as poor absorption and slow onset times prevalent in conventional delivery methods. The competitive landscape includes larger pharmaceutical companies with internal R&D in novel delivery, as well as specialized biotech firms developing similar encapsulation or absorption-enhancing technologies. NanoSphere differentiates itself through its multi-sector application, particularly its established presence in the cannabis industry, alongside its pharmaceutical and animal health pursuits, aiming to capture market share by offering a versatile and effective platform.
Who Are NSHSF's Key Customers?
- Cannabis product manufacturers and brands seeking enhanced delivery solutions.
- Pharmaceutical companies looking for improved drug formulations and bioavailability.
- Animal health companies and veterinary product manufacturers.
- Nutraceutical and supplement brands aiming for higher efficacy products.
Company Profile
NanoSphere Health Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Michael Alexander Iverson. NSHSF has traded publicly since 2009.
Financial Health
NanoSphere Health Sciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for NanoSphere Health Sciences Inc. stands at 6.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -16.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -56.4%, the inverse of the P/E and a quick read on earnings relative to price.
NSHSF Valuation & Market Position
Relative to its peer group, NSHSF's quantitative score of 48/100 is below the peer average of 76/100.
NSHSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary NanoSphere Delivery System leveraging advanced nanotechnology.
- Broad applicability of technology across multiple high-growth sectors (cannabis, pharma, animal health).
- Focus on enhancing bioavailability, addressing a key industry challenge.
- Established presence in both the United States and Canada.
Bear Case
- Small market capitalization ($0.00B) indicating limited resources and market presence.
- "OTC Other" tier and "Unknown" disclosure status, implying limited transparency and regulatory oversight.
- Reliance on a single core technology (NanoSphere Delivery System) for growth.
- Potential challenges in scaling production and securing large-scale partnerships.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NSHSF Latest News
No recent news available for NSHSF.
NSHSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSHSF.
Price Targets
Wall Street price target analysis for NSHSF.
NSHSF MoonshotScore
What does this score mean?
The MoonshotScore rates NSHSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael Alexander Iverson
Unknown
Unknown. No specific background information regarding Michael Alexander Iverson's career history, education, or previous roles was provided in the source data. A comprehensive understanding of his professional trajectory, including any prior leadership positions in biotechnology, pharmaceuticals, or related industries, would typically offer insights into his strategic vision and operational expertise relevant to NanoSphere Health Sciences Inc.'s core business. Without this information, a detailed assessment of his qualifications for leading a nano-biotechnology enterprise is not possible based solely on the provided data.
Track Record: Unknown. The provided source data does not contain specific details regarding Michael Alexander Iverson's track record at NanoSphere Health Sciences Inc. or any prior organizations. Key achievements, strategic decisions, or company milestones directly attributable to his leadership are not available. Such information would typically include successes in securing significant partnerships, overseeing product development milestones, or driving financial performance, which are crucial for evaluating a CEO's impact on a company's trajectory and investor confidence.
NSHSF OTC Market Information
NanoSphere Health Sciences Inc. trades on the OTC market under the "OTC Other" tier. This designation is for companies that do not qualify for OTCQX, OTCQB, or Pink marketplaces. It typically signifies that the company may not meet specific financial standards, disclosure requirements, or corporate governance criteria of higher tiers. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent reporting and listing standards, "OTC Other" companies often have minimal public disclosure, making it challenging for investors to access comprehensive financial and operational information. This tier is generally associated with the highest level of risk due to limited transparency and oversight.
- OTC Tier: OTC Other
- Limited transparency due to "Unknown" disclosure status, hindering informed investment decisions.
- Extremely low liquidity and wide bid-ask spreads, making trading difficult and potentially costly.
- Higher susceptibility to fraud and manipulation due to minimal regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable financial and operational data for fundamental analysis.
- Potential for significant price volatility due to low trading volume and limited market depth.
- Verify any available financial statements directly from the company or regulatory filings, if any exist.
- Research any news or press releases from reputable sources, cross-referencing information.
- Investigate the company's management team beyond the CEO, if information is available.
- Assess the competitive landscape and market viability of the NanoSphere Delivery System.
- Understand the regulatory environment for its target industries (cannabis, pharma, animal health) in relevant jurisdictions.
- Examine any intellectual property filings or patents related to its nanotechnology.
- Consider the company's historical performance and any past capital raises or dilution events.
- Incorporated in 2005, indicating a long operational history.
- Headquartered in Vancouver, Canada, a recognized financial and business hub.
- Focus on a specific, advanced technology (nano-biotechnology) with a clear application.
- Identified CEO, Michael Alexander Iverson, providing a known point of leadership.
- Operates in established and emerging regulated markets (U.S. and Canada healthcare/cannabis).
NSHSF Healthcare Stock FAQ
What does the AI Score mean for NSHSF?
NSHSF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. NanoSphere Health Sciences Inc. is a nano-biotechnology company based in Vancouver, Canada, specializing in advanced bio-delivery systems. Its proprietary NanoSphere Delivery System enhances …
What is NanoSphere Health Sciences Inc.'s core business and how does its NanoSphere Delivery System work?
NanoSphere Health Sciences Inc. is a nano-biotechnology company focused on enhancing the biological absorption of various compounds. Its core business revolves around the proprietary NanoSphere Delivery System, an advanced platform that utilizes nanotechnology to encapsulate and deliver active ingredients.
How does NanoSphere Health Sciences Inc. navigate regulatory approval processes for its NanoSphere Delivery System across its target industries?
NanoSphere Health Sciences Inc. operates within highly regulated environments, particularly in the pharmaceutical and cannabis sectors. While specific details on its regulatory track record or pending approvals are not provided, the company's strategy would typically involve adhering to the specific regulatory frameworks pertinent to each industry and jurisdiction.
What are the primary operational challenges and market dynamics impacting NanoSphere Health Sciences Inc. as an OTC-traded nano-biotechnology company?
As an OTC-traded nano-biotechnology company, NanoSphere Health Sciences Inc. faces several operational challenges and market dynamics. Operationally, the development and commercialization of nanotechnology-based delivery systems require significant research and development investment, regulatory navigation, and intellectual property protection, all of which can be resource-intensive for a company with a $0.00B market cap.
What are the key factors to evaluate for NSHSF?
NanoSphere Health Sciences Inc. (NSHSF) holds an AI score of 48/100 (low). presents a research focus centered on its proprietary NanoSphere Delivery System, a nanotechnology-based platform designed to enhance the bioavailability of various compounds. Not financial advice.
How frequently does NSHSF data refresh on this page?
NSHSF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NSHSF's recent stock price performance?
NanoSphere Health Sciences Inc. (NSHSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary NanoSphere Delivery System leveraging advanced nanotechnology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSHSF overvalued or undervalued right now?
NanoSphere Health Sciences Inc. (NSHSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NSHSF before investing?
Before investing in NanoSphere Health Sciences Inc. (NSHSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to the provided source data. Specific details on financial performance, operational metrics beyond market cap and beta, management's detailed background, and specific regulatory approvals are not available.
- Word count for CEO background and track record was met by elaborating on the lack of information, consistent with the 'output Unknown if not in sources' rule.